Today's After-Hours Stock Movers:

PFSweb, Inc. (NASDAQ: PFSW) 33% HIGHER; Q4 Total orders fulfilled increased 88% to nearly 11 million orders. Customer orders processed during November and December 2020 exceeded four million orders each month.

Apyx Medical Corporation (NASDAQ: APYX) 23% HIGHER; Advanced Energy Sales of approximately $9.5 to $9.8 million in Q4, up 39% to 43% year-over-year.

Virgin Galactic Holdings, Inc. (NYSE: SPCE) 10.9% HIGHER; Cathie Wood Plans to Launch Space ETF

DermTech (NASDAQ: DMTK) 6% HIGHER; Director, Matthew Posard, bought 33,898 shares on 01/11 at $29.50.

Evoke Pharma, Inc. (Nasdaq: EVOK) 3.7% LOWER; announced that it intends to offer and sell shares of its common stock in a “firm commitment” underwritten public offering.

AeroVironment, Inc. (NASDAQ: AVAV) 3.3% LOWER; announced that they have entered into a definitive agreement under which AeroVironment will acquire Arcturus UAV for a total purchase price of $405 million, including $355 million in cash and $50 million in AeroVironment stock. The transaction, which was unanimously approved by the AeroVironment and Arcturus UAV Boards of Directors, is expected to accelerate AeroVironments strategy to drive profitable growth and value by expanding into attractive adjacent segments and by broadening its capabilities and customer footprint.

Nordstrom, Inc. (NYSE: JWN) 3.2% LOWER; Announced a net sales decline of approximately 22 percent for the nine-week holiday period ended January 2, 2021, compared with the nine weeks ended January 4, 2020.

Johnson & Johnson (NYSE: JNJ) 1.1% HIGHER; Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Companys single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020. The Phase 1/2a interim analysis showed that the Companys COVID-19 vaccine candidate induced an immune response and was generally well-tolerated across all study participants. Data demonstrated that, after a single vaccination, neutralizing antibodies against COVID-19 were detected in over 90 percent of study participants at Day 29 and 100 percent of participants aged 18-55 years at Day 57. These neutralizing antibodies remained stable through Day 71, currently the latest timepoint available in this ongoing study, in all participants aged 18-55 years. Data on durability of immune responses in trial participants aged over 65 years will be available in late January and longer-term follow-up to one year is planned.